Conjugate Or Complex Includes Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/197.11)
  • Patent number: 10946086
    Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 16, 2021
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Amardeep Singh Bhupender Bhalla, Robert G. K. Donald, Jianxin Gu, Kathrin Ute Jansen, Rajesh Kumar Kainthan, Lakshmi Khandke, Jin-Hwan Kim, Paul Liberator, Avvari Krishna Prasad, Mark Edward Ruppen, Ingrid Lea Scully, Suddham Singh, Cindy Xudong Yang
  • Patent number: 10787484
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Patent number: 10610576
    Abstract: The present description relates to glycoconjugates, glycoconjugate immunogens and glycoconjugate vaccines comprising carbohydrate antigens coupled to immunogenic carrier proteins, or materials used for detection and screening of resulting antibodies. Improved methods of more directly and precisely conjugating carbohydrate antigens to free thiol groups of immunogenic carrier proteins are described, including “click-chemistry” approaches based on photocatalytic thiol-ene reactions.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: April 7, 2020
    Assignee: Koranex Capital
    Inventors: Tze Chieh Shiao, Rene Roy
  • Patent number: 10428112
    Abstract: The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: October 1, 2019
    Assignees: RIKEN, Animal Allergy Clinical Laboratories Inc., Nippon Zenyaku Kogyo Co., Ltd.
    Inventors: Kenichi Masuda, Yasuyuki Ishii, Toshihiro Tsukui
  • Patent number: 10272147
    Abstract: An injectable immunogenic composition comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of Neisseria meningitidis, wherein said capsular saccharides are conjugated to carrier protein(s) and/or are oligosaccharides, and wherein (i) the composition comprises <50 ?g meningococcal saccharide per dose, and/or (ii) the composition further comprises an antigen from one or more of: (a) serogroup B N. meningitidis; (b) Haemophilus influenzae type B; and/or (c) Streptococcus pneumoniae. Saccharide antigens in the compositions are generally conjugated to a carrier.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: April 30, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Paolo Costantino
  • Patent number: 10201544
    Abstract: This invention relates to a solid phase method of synthesizing biomolecule-drug conjugates. In particular, this invention relates to a solid phase method of synthesizing antibody-drug conjugates (ADCs). This invention also relates to intermediate methods of producing immobilized, chemically modified biomolecules, e.g. antibodies. The invention also relates to various uses of capture resins and to biomolecule-drug conjugates, intermediate products and compositions prepared by the methods of the invention.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: February 12, 2019
    Assignee: ADC Biotechnology Ltd.
    Inventors: David J. Evans, Colin M. McKee
  • Patent number: 10155014
    Abstract: Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant Listeria bacteria, cyclase and/or phosphodiesterase nucleic acid or protein compositions, etc. The subject methods and compositions find use in a variety of applications, including therapeutic applications.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: December 18, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Daniel A. Portnoy, Joshua J. Woodward
  • Patent number: 10143728
    Abstract: The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer lasting effect in the patient compared to an animal-protein-containing botulinum toxin composition.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 4, 2018
    Assignee: Medy-Tox Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hyun Jee Kim, Chang Hoon Rhee
  • Patent number: 10124050
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: November 13, 2018
    Assignee: Pfizer Inc.
    Inventors: Wendy Jo Watson, Luis Pascual Jodar Martin-Montalvo, Raul Enrique Isturiz, Ralf Rene Reinert
  • Patent number: 9982252
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: May 29, 2018
    Assignee: BIOATLA, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 9782466
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: October 10, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Constantino
  • Patent number: 9782467
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: October 10, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Paolo Costantino
  • Patent number: 9669084
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 6, 2017
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Patent number: 9662386
    Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 30, 2017
    Assignee: Osaka University
    Inventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai
  • Patent number: 9623100
    Abstract: The present invention relates to immunogenic conjugates comprising S. aureus serotype 5 and 8 capsular polysaccharides conjugated to carrier proteins and methods for their preparation and use. Methods for making the immunogenic conjugates of the invention involve covalent conjugation of the capsular polysaccharides with the carrier proteins using conjugation chemistry involving either 1,1-carbonyl-di-1,2,4-triazole (CDT) or 3-(2-pyridyldithio)-propionyl hydrazide (PDPH).
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: April 18, 2017
    Assignee: Wyeth LLC
    Inventors: Stephen John Freese, Annaliesa Anderson, Viliam Pavliak, Kathrin Ute Jansen, Ingrid Lea Scully, Tracy Dee Scott, Jasdeep Singh Nanra, A. Krishna Prasad, Bruce Arthur Green
  • Patent number: 9452207
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide: MenC saccharide is >1.
    Type: Grant
    Filed: January 20, 2009
    Date of Patent: September 27, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Paolo Costantino
  • Patent number: 9408819
    Abstract: The present disclosure is directed to a novel nutritional formula for treating or preventing systemic inflammation in a subject. The nutritional formula comprises a therapeutically effective amount of inactivated Lactobacillus rhamnosus GG (LGG).
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: August 9, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Udo Herz, Robert J. McMahon, William Michael Russell, Josef Neu
  • Patent number: 9399060
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 26, 2016
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Patent number: 9328158
    Abstract: Dextrans produced by lactic acid bacteria Leuconostoc mesenteroides and consisting of linear ?1,6-glucan chains modified with short side-chains composed of consecutive ?1,6-linked glucose residues were linked to a carrier protein. Three dextrans, namely Dextran-5K, Dextran-3.5K and Dextran-1.5K, with molecular masses of 5,000 Da, 3,500 Da and 1,500 Da, respectively, were modified with a diamino group-containing linker, followed by the introduction of maleimido functionality and conjugation to thiolated tetanus toxoid (TT), yielding Dextran-5K-TT, Dextran-3.5K-TT and Dextran-1.5K-TT conjugates. Studies performed with post-immune sera of mice and rabbits immunized with dextran-based glycococonjugates demonstrated cross-reactivity with LPS from typeable and non-typeable H. pylori strains and selected mutants. The post-immune sera from rabbits that received the conjugates exhibited functional activity against ?1,6-glucan-positive strains of H.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: May 3, 2016
    Assignee: National Research Council of Canada
    Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
  • Patent number: 9265839
    Abstract: Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 23, 2016
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
  • Patent number: 9265840
    Abstract: Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: February 23, 2016
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
  • Patent number: 9205143
    Abstract: The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumoccocal infections using said novel pneumococcal vaccines.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: December 8, 2015
    Assignee: Coley Pharmaceutical Group Inc.
    Inventors: Heather Lynn Davis, Arthur Mertz Krieg, Nicolai Lohse, Lars Ostergaard, Henrik Carl Schonheyder, Ole Schmeltz Sogaard
  • Patent number: 9173932
    Abstract: The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: November 3, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Shousun Chen Szu, Zuzana Kossaczka, John B. Robbins
  • Patent number: 9161975
    Abstract: The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: October 20, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Normand Blais, Anne-Marie Lanteigne, Daniel Larocque, Corey Patrick Mallett
  • Patent number: 9061048
    Abstract: Methods of modulating type-I interferon production in a cell are provided. Aspects of the methods include modulating cytosolic cyclic di-adenosine monophosphate (c-di-AMP) activity in the cell in a manner sufficient to modulate type-I interferon production in the cell. Additional aspects of the invention include c-di-AMP activity modulatory compositions, e.g., c-di-AMP, mutant Listeria bacteria, cyclase and/or phosphodiesterase nucleic acid or protein compositions, etc. The subject methods and compositions find use in a variety of applications, including therapeutic applications.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: June 23, 2015
    Assignee: The Regents of the University of California
    Inventors: Daniel A. Portnoy, Joshua J. Woodward
  • Publication number: 20150139998
    Abstract: The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 21, 2015
    Inventors: Johannes Huebner, Otto Holst, Christian Theilacker, Karolina Kruszynska, Stefan Geiss-Liebisch, Agnieszka Beczala
  • Patent number: 9034337
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.
    Type: Grant
    Filed: February 23, 2007
    Date of Patent: May 19, 2015
    Assignee: Prothena Biosciences Limited
    Inventors: Dale B. Schenk, Eliezar Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
  • Publication number: 20150132339
    Abstract: The efficacy of S. pneumoniae vaccines can be enhanced by adjuvanting S. pneumoniae saccharide and/or protein antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The S. pneumoniae antigen can also be adsorbed to the metal salt.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Simone Bufali, Paolo Costantino, Michele Pallaoro, Derek O'hagan, Rino Rappuoli, Manmohan Singh
  • Patent number: 9023363
    Abstract: The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: May 5, 2015
    Assignee: International Vaccine Institute
    Inventors: Cecil Czerkinsky, Manki Song
  • Publication number: 20150118263
    Abstract: The present application relates to glycoengineered outer membrane vesicles obtained from recombinant, gram-negaetive bacteria comprising hetereologous DNA encoding an enzyme or enzymes that produce a heterologous glycan that replaces all or a portion of the naturally-occurring O antigen in the lipopolysaccharides of the bacteria. Also provided by the present application are immunogenic compositions and vaccines prepared from the glycoengineered outer membrane vesicles expressing the heterologous glycans at their surface.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 30, 2015
    Applicant: The Governors of the University of Alberta
    Inventors: Mario Feldman, Nancy Price, Fatima Garcia-Quintanilla, Maria Veronica Ielmini
  • Patent number: 9011871
    Abstract: The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and optionally S. Paratyphi B, wherein the conjugates comprise a hapten antigen and a carrier antigen, wherein at least one of the hapten antigens or carrier antigens is characteristic of the Salmonella enterica serovar. The present invention also provides Salmonella enterica serovar reagent strains to produce the multivalent conjugate vaccines and attenuated Salmonella enterica serovars for use as vaccines.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: University of Maryland, Baltimore
    Inventors: Myron M. Levine, James E. Galen, Sharon M. Tennant, Raphael Simon
  • Patent number: 9011870
    Abstract: The invention relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allows the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, said bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to said carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also provided is a pharmaceutical (e.g. vaccine) composition comprising an antigen-loaded immunogenic carrier complex of the invention.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: April 21, 2015
    Assignee: Applied Nanosystems B.V.
    Inventors: Cornelis Johannes Leenhouts, Maarten Leonardus Van Roosmalen, Tjibbe Bosma
  • Publication number: 20150104479
    Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.
    Type: Application
    Filed: May 22, 2013
    Publication date: April 16, 2015
    Applicant: NOVARTIS AG
    Inventors: Maria Rosaria Romano, Francesca Micoli, Francesco Berti, Roberto Adamo, Paolo Costantino
  • Patent number: 8999354
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 7, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Publication number: 20150093412
    Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, National Research Council of Canada
    Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
  • Publication number: 20150093411
    Abstract: The present invention provides multivalent chimeric conjugate vaccine molecule and methods of using the conjugate to immunize subjects against bacterial infections. A conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. Accordingly, the conjugate molecule provides immune protection against multiple types of bacteria in a single vaccines. In particular, conjugate molecules of the invention are used to prevent or attenuate Group B Streptococcus and meningococcal infections.
    Type: Application
    Filed: June 27, 2014
    Publication date: April 2, 2015
    Inventors: Francis Michon, John Kim, Arun Sarkar, Catherine Uitz
  • Publication number: 20150079129
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Carine CAPIAU, Marguerite DESCHAMPS, Pierre Michel DESMONS, Craig Antony Joseph LAFERRIERE, Jan POOLMAN, Jean-Paul PRIEELS
  • Patent number: 8980277
    Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: March 17, 2015
    Assignee: Novartis AG
    Inventor: Mariagrazia Pizza
  • Patent number: 8980278
    Abstract: The present invention is directed to a bio-functionalized stimulus-responsive dissolvable PEG-hydrogel. This inventive stimulus-responsive dissolvable PEG-hydrogel comprises a matrix of PEG-polymers, which are modified to contain at least one multifunctional fusion protein, the multifunctional fusion protein preferably comprising as components a substrate binding peptide (SBP), preferably a repetitive RGD-binding peptide and/or a ZZ-binding domain, preferably a tag for purification, and at least one N- and/or C-terminal linker. The present invention is furthermore directed to the use of such inventive stimulus-responsive dissolvable PEG-hydrogels in the treatment of lesions, in surgical dressings, for wound treating, for soft and hard tissue regeneration, for the treatment of wounds in the oral cavity, in the field of ophthalmology, in the field of periodontal defects, etc. The invention also describes a method of treatment for such diseases.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 17, 2015
    Assignees: Universitaetsklinikum Freiburg, Albert-Ludwigs-Universitaet Freigburg
    Inventors: Thorsten Steinberg, Wilfried Weber, Raphael Guebeli, Pascal Tomakidi, Dougal Laird
  • Publication number: 20150071961
    Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 12, 2015
    Applicant: University of Florida Research Foundation, Inc.
    Inventor: Raymond J. Bergeron, JR.
  • Patent number: 8974799
    Abstract: The invention provides a process for preparing a conjugate of a S. aureus type 5 or type 8 capsular polysaccharide and a carrier molecule, comprising the steps of: (a) depolymerizing the capsular polysaccharide, to give a polysaccharide fragment; (b) oxidizing the fragment in order to introduce an aldehyde group into at least one saccharide residue in the fragment, to give an oxidized saccharide residue; and (c) coupling the oxidized saccharide residue to a carrier molecule via the aldehyde group, thereby giving the conjugate. The coupling in step (c) may be direct, or may be via a linker molecule. The invention also provides a conjugate obtained or obtainable by this process.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Francesco Berti, Paolo Costantino, Maria Rosaria Romano
  • Patent number: 8975043
    Abstract: Novel enzymes, processes and antigenic structures useful in producing vaccines and compounds useful in combating gram-negative bacteria are described. Enzymes were isolated from the slime mold Dictyostelium discoideum and used to specifically degrade lipopolysaccharide (LPS). Enzymatic degradation permits residues of the LPS molecule, including immunogenic epitopes of the core oligosaccharide portion of the LPS, to remain unmodified during this enzymatic removal of fatty acids from the lipid A region of the LPS molecule.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: March 10, 2015
    Assignee: National Research Council of Canada
    Inventors: Andrew Cox, Dhamodharan Neelamegan, Ian Schoenhofen, Frank St. Michael, James Richards
  • Patent number: 8956618
    Abstract: Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: February 17, 2015
    Assignees: The Texas A&M University System, The Board of Trustees of the University of Arkansas
    Inventors: Luc Berghman, Walter Bottje, Billy Hargis, Sherryll Layton
  • Patent number: 8956625
    Abstract: The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus are provided.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: February 17, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Herve De Hemptinne, Michel Duchene, Anne Mary, Marc Sonveaux
  • Publication number: 20150044254
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Applicant: GLYCOVAXYN AG
    Inventors: Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
  • Publication number: 20150037368
    Abstract: The present invention relates to methods of reducing flocculation in an immunogenic composition, where said immunogenic composition comprises (a) Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and (b) at least one non-PRP antigen. The invention further relates to kits comprising (i) a first composition comprising a Haemophilus influenzae B capsular polysaccharide or oligosaccharide (PRP) and a polyanionic polymer, and (ii) a second composition comprising a non-PRP antigen adsorbed onto an adjuvant with a zero point charge greater than 8.
    Type: Application
    Filed: October 8, 2014
    Publication date: February 5, 2015
    Inventors: Nathalie Marie-Josephe GARCON, Dominique LEMOINE, Florence Emilie Jeanne Francoise WAUTERS
  • Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Publication number: 20150010592
    Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Applicant: GLYCOVAXYN AG
    Inventors: Michael Wacker, Michael Kowarik, Michael Wetter
  • Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • Patent number: 8926986
    Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: January 6, 2015
    Assignees: National Research Council of Canada, The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins